Laura San Segundo Payo-rekin lankidetzan egindako argitalpenak (3)

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2012

  1. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma

    Annals of Hematology, Vol. 91, Núm. 2, pp. 257-269

2010

  1. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

    Haematologica, Vol. 95, Núm. 5, pp. 794-803